Philadelphia Center for Anti-Aging
- NAD IV Therapy
- Vitamin IV Therapy
- PRP Therapy
- Arthritis Treatment
- Peptide Therapy
Philadelphia, PA
Philadelphia has an Ivy-trained physician network and stringent Pennsylvania compounding oversight, and peptide therapy has grown into a visible slice of the local wellness market. The clinics we track across Rittenhouse, University City, Society Hill, and the Main Line range from physician-led longevity practices to medspa-adjacent wellness offices offering sermorelin blends and growth hormone peptides. Most local prescribers have training or admitting privileges within the Penn Medicine, Jefferson, and CHOP network. The scene here skews toward academic-affiliated physicians running longevity practices alongside concierge medicine. The regulatory landscape shifted sharply in 2023 and 2024 when the FDA placed several widely prescribed peptides on its Category 2 bulk substances list, restricting which ingredients compounding pharmacies could legally source. That changed access overnight for BPC-157, CJC-1295, ipamorelin, and thymosin beta-4. Sermorelin and tesamorelin remain FDA-approved for specific indications, and reputable Philadelphia clinics now draw a clearer line between approved peptides and off-label research compounds than they did two years ago.
Regulatory context
Most research peptides used in regenerative medicine (BPC-157, TB-500, CJC-1295, ipamorelin) are not FDA-approved drugs. Sermorelin and tesamorelin hold FDA approvals for specific indications. The FDA placed several peptides into Category 2 on its Bulk Drug Substances Nominated for Use in Compounding list during 2023 and 2024, restricting 503A pharmacy sourcing. Section 503A covers traditional patient-specific compounding; Section 503B covers FDA-registered outsourcing facilities held to cGMP.
The Pennsylvania State Board of Pharmacy inspects compounding pharmacies for USP compliance. Non-resident pharmacies shipping peptides into Pennsylvania must hold a current non-resident pharmacy registration. The Board publishes disciplinary actions under the Bureau of Professional and Occupational Affairs.